Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride
Identifieur interne : 002279 ( Main/Corpus ); précédent : 002278; suivant : 002280Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride
Auteurs : Juha O. Rinne ; Arto Laihinen ; Hanna Ruottinen ; Ulla Ruotsalainen ; Kjell N Gren ; Pertti Lehikoinen ; Vesa Oikonen ; U. K. RinneSource :
- Journal of the Neurological Sciences [ 0022-510X ] ; 1995.
Abstract
Striatal dopamine D2 receptors were studied, using positron emission tomography (PET), in 10 patients with early Parkinson's disease without any antiparkinsonian medication and in 14 healthy controls. [11C]Raclopride was used as ligand and an equilibrium method was applied. The maximum count of receptors (Bmax) and their dissociation constant (Kd) were calculated according to the Scatchard principle. In parkinsonian patients, the Bmax of D2 receptors was increased in the putamen contralateral to the predominant symptoms, as compared to the opposite putamen, by 33% (p = 0.0008). In the caudate nucleus no significant side to side differences was noted. On comparison with age-matched healthy controls, Bmax values in the putamen (p = 0.0012) but not in the caudate nucleus contralateral to the side of predominant clinical symptoms were increased in PD patients. The Kd values were unchanged. The difference in putaminal Bmax values between the opposite hemispheres correlated with the difference in the severity of parkinsonian motor symptoms between the two body sides (r = 0.69, p = 0.03). The present results show that there is both a relative and absolute increase in the number of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease.
Url:
DOI: 10.1016/0022-510X(95)00137-Q
Links to Exploration step
ISTEX:809F6EC7C0EA6A5FF989A13C81E2B878D81F912BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride</title><author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name><affiliation><mods:affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Laihinen, Arto" sort="Laihinen, Arto" uniqKey="Laihinen A" first="Arto" last="Laihinen">Arto Laihinen</name><affiliation><mods:affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Ruottinen, Hanna" sort="Ruottinen, Hanna" uniqKey="Ruottinen H" first="Hanna" last="Ruottinen">Hanna Ruottinen</name><affiliation><mods:affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Ruotsalainen, Ulla" sort="Ruotsalainen, Ulla" uniqKey="Ruotsalainen U" first="Ulla" last="Ruotsalainen">Ulla Ruotsalainen</name><affiliation><mods:affiliation>Turku University Cyclotron-PET Center, PET Unit, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="N Gren, Kjell" sort="N Gren, Kjell" uniqKey="N Gren K" first="Kjell" last="N Gren">Kjell N Gren</name><affiliation><mods:affiliation>Turku University Cyclotron-PET Center, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Lehikoinen, Pertti" sort="Lehikoinen, Pertti" uniqKey="Lehikoinen P" first="Pertti" last="Lehikoinen">Pertti Lehikoinen</name><affiliation><mods:affiliation>Turku University Cyclotron-PET Center, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Oikonen, Vesa" sort="Oikonen, Vesa" uniqKey="Oikonen V" first="Vesa" last="Oikonen">Vesa Oikonen</name><affiliation><mods:affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name><affiliation><mods:affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:809F6EC7C0EA6A5FF989A13C81E2B878D81F912B</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1016/0022-510X(95)00137-Q</idno><idno type="url">https://api.istex.fr/document/809F6EC7C0EA6A5FF989A13C81E2B878D81F912B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002279</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride</title><author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name><affiliation><mods:affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Laihinen, Arto" sort="Laihinen, Arto" uniqKey="Laihinen A" first="Arto" last="Laihinen">Arto Laihinen</name><affiliation><mods:affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Ruottinen, Hanna" sort="Ruottinen, Hanna" uniqKey="Ruottinen H" first="Hanna" last="Ruottinen">Hanna Ruottinen</name><affiliation><mods:affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Ruotsalainen, Ulla" sort="Ruotsalainen, Ulla" uniqKey="Ruotsalainen U" first="Ulla" last="Ruotsalainen">Ulla Ruotsalainen</name><affiliation><mods:affiliation>Turku University Cyclotron-PET Center, PET Unit, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="N Gren, Kjell" sort="N Gren, Kjell" uniqKey="N Gren K" first="Kjell" last="N Gren">Kjell N Gren</name><affiliation><mods:affiliation>Turku University Cyclotron-PET Center, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Lehikoinen, Pertti" sort="Lehikoinen, Pertti" uniqKey="Lehikoinen P" first="Pertti" last="Lehikoinen">Pertti Lehikoinen</name><affiliation><mods:affiliation>Turku University Cyclotron-PET Center, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Oikonen, Vesa" sort="Oikonen, Vesa" uniqKey="Oikonen V" first="Vesa" last="Oikonen">Vesa Oikonen</name><affiliation><mods:affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name><affiliation><mods:affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of the Neurological Sciences</title><title level="j" type="abbrev">JNS</title><idno type="ISSN">0022-510X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1995">1995</date><biblScope unit="volume">132</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="156">156</biblScope><biblScope unit="page" to="161">161</biblScope></imprint><idno type="ISSN">0022-510X</idno></series><idno type="istex">809F6EC7C0EA6A5FF989A13C81E2B878D81F912B</idno><idno type="DOI">10.1016/0022-510X(95)00137-Q</idno><idno type="PII">0022-510X(95)00137-Q</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-510X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Striatal dopamine D2 receptors were studied, using positron emission tomography (PET), in 10 patients with early Parkinson's disease without any antiparkinsonian medication and in 14 healthy controls. [11C]Raclopride was used as ligand and an equilibrium method was applied. The maximum count of receptors (Bmax) and their dissociation constant (Kd) were calculated according to the Scatchard principle. In parkinsonian patients, the Bmax of D2 receptors was increased in the putamen contralateral to the predominant symptoms, as compared to the opposite putamen, by 33% (p = 0.0008). In the caudate nucleus no significant side to side differences was noted. On comparison with age-matched healthy controls, Bmax values in the putamen (p = 0.0012) but not in the caudate nucleus contralateral to the side of predominant clinical symptoms were increased in PD patients. The Kd values were unchanged. The difference in putaminal Bmax values between the opposite hemispheres correlated with the difference in the severity of parkinsonian motor symptoms between the two body sides (r = 0.69, p = 0.03). The present results show that there is both a relative and absolute increase in the number of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Juha O. Rinne</name><affiliations><json:string>Department of Neurology, University of Turku, SF-20520 Turku, Finland</json:string></affiliations></json:item><json:item><name>Arto Laihinen</name><affiliations><json:string>Department of Neurology, University of Turku, SF-20520 Turku, Finland</json:string></affiliations></json:item><json:item><name>Hanna Ruottinen</name><affiliations><json:string>Department of Neurology, University of Turku, SF-20520 Turku, Finland</json:string></affiliations></json:item><json:item><name>Ulla Ruotsalainen</name><affiliations><json:string>Turku University Cyclotron-PET Center, PET Unit, Turku, Finland</json:string></affiliations></json:item><json:item><name>Kjell Någren</name><affiliations><json:string>Turku University Cyclotron-PET Center, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland</json:string></affiliations></json:item><json:item><name>Pertti Lehikoinen</name><affiliations><json:string>Turku University Cyclotron-PET Center, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland</json:string></affiliations></json:item><json:item><name>Vesa Oikonen</name><affiliations><json:string>Department of Neurology, University of Turku, SF-20520 Turku, Finland</json:string></affiliations></json:item><json:item><name>U.K. Rinne</name><affiliations><json:string>Department of Neurology, University of Turku, SF-20520 Turku, Finland</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Clinical section</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dopamine receptors</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>D2 receptors</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Positron emission tomography</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Raclopride</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Striatal dopamine D2 receptors were studied, using positron emission tomography (PET), in 10 patients with early Parkinson's disease without any antiparkinsonian medication and in 14 healthy controls. [11C]Raclopride was used as ligand and an equilibrium method was applied. The maximum count of receptors (Bmax) and their dissociation constant (Kd) were calculated according to the Scatchard principle. In parkinsonian patients, the Bmax of D2 receptors was increased in the putamen contralateral to the predominant symptoms, as compared to the opposite putamen, by 33% (p = 0.0008). In the caudate nucleus no significant side to side differences was noted. On comparison with age-matched healthy controls, Bmax values in the putamen (p = 0.0012) but not in the caudate nucleus contralateral to the side of predominant clinical symptoms were increased in PD patients. The Kd values were unchanged. The difference in putaminal Bmax values between the opposite hemispheres correlated with the difference in the severity of parkinsonian motor symptoms between the two body sides (r = 0.69, p = 0.03). The present results show that there is both a relative and absolute increase in the number of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease.</abstract><qualityIndicators><score>6.174</score><pdfVersion>1.3</pdfVersion><pdfPageSize>611.84 x 792.28 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>1291</abstractCharCount><pdfWordCount>3774</pdfWordCount><pdfCharCount>24034</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>200</abstractWordCount></qualityIndicators><title>Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride</title><pii><json:string>0022-510X(95)00137-Q</json:string></pii><genre><json:string>research-article</json:string></genre><serie><volume>Volume II</volume><pages><last>163</last><first>153</first></pages><genre></genre><language><json:string>unknown</json:string></language><title>Recent Developments in Parkinson's Disease</title></serie><host><volume>132</volume><pii><json:string>S0022-510X(00)X0011-1</json:string></pii><pages><last>161</last><first>156</first></pages><issn><json:string>0022-510X</json:string></issn><issue>2</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>Journal of the Neurological Sciences</title><publicationDate>1995</publicationDate></host><categories><wos><json:string>CLINICAL NEUROLOGY</json:string><json:string>NEUROIMAGING</json:string><json:string>NEUROSCIENCES</json:string></wos></categories><publicationDate>1995</publicationDate><copyrightDate>1995</copyrightDate><doi><json:string>10.1016/0022-510X(95)00137-Q</json:string></doi><id>809F6EC7C0EA6A5FF989A13C81E2B878D81F912B</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/809F6EC7C0EA6A5FF989A13C81E2B878D81F912B/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/809F6EC7C0EA6A5FF989A13C81E2B878D81F912B/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/809F6EC7C0EA6A5FF989A13C81E2B878D81F912B/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/809F6EC7C0EA6A5FF989A13C81E2B878D81F912B/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1995</date></publicationStmt><notesStmt><note type="content">Section title: Research article</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride</title><author><persName><forename type="first">Juha O.</forename><surname>Rinne</surname></persName><note type="correspondence"><p>Corresponding author. Tel.: (+358-21) 261 1700; Fax: (+358-21) 261 1709.</p></note><affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</affiliation></author><author><persName><forename type="first">Arto</forename><surname>Laihinen</surname></persName><affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</affiliation></author><author><persName><forename type="first">Hanna</forename><surname>Ruottinen</surname></persName><affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</affiliation></author><author><persName><forename type="first">Ulla</forename><surname>Ruotsalainen</surname></persName><affiliation>Turku University Cyclotron-PET Center, PET Unit, Turku, Finland</affiliation></author><author><persName><forename type="first">Kjell</forename><surname>Någren</surname></persName><affiliation>Turku University Cyclotron-PET Center, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland</affiliation></author><author><persName><forename type="first">Pertti</forename><surname>Lehikoinen</surname></persName><affiliation>Turku University Cyclotron-PET Center, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland</affiliation></author><author><persName><forename type="first">Vesa</forename><surname>Oikonen</surname></persName><affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</affiliation></author><author><persName><forename type="first">U.K.</forename><surname>Rinne</surname></persName><affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</affiliation></author></analytic><monogr><title level="j">Journal of the Neurological Sciences</title><title level="j" type="abbrev">JNS</title><idno type="pISSN">0022-510X</idno><idno type="PII">S0022-510X(00)X0011-1</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1995"></date><biblScope unit="volume">132</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="156">156</biblScope><biblScope unit="page" to="161">161</biblScope></imprint></monogr><idno type="istex">809F6EC7C0EA6A5FF989A13C81E2B878D81F912B</idno><idno type="DOI">10.1016/0022-510X(95)00137-Q</idno><idno type="PII">0022-510X(95)00137-Q</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1995</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Striatal dopamine D2 receptors were studied, using positron emission tomography (PET), in 10 patients with early Parkinson's disease without any antiparkinsonian medication and in 14 healthy controls. [11C]Raclopride was used as ligand and an equilibrium method was applied. The maximum count of receptors (Bmax) and their dissociation constant (Kd) were calculated according to the Scatchard principle. In parkinsonian patients, the Bmax of D2 receptors was increased in the putamen contralateral to the predominant symptoms, as compared to the opposite putamen, by 33% (p = 0.0008). In the caudate nucleus no significant side to side differences was noted. On comparison with age-matched healthy controls, Bmax values in the putamen (p = 0.0012) but not in the caudate nucleus contralateral to the side of predominant clinical symptoms were increased in PD patients. The Kd values were unchanged. The difference in putaminal Bmax values between the opposite hemispheres correlated with the difference in the severity of parkinsonian motor symptoms between the two body sides (r = 0.69, p = 0.03). The present results show that there is both a relative and absolute increase in the number of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease.</p></abstract><textClass><keywords scheme="keyword"><list><head>Article category</head><item><term>Clinical section</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Dopamine receptors</term></item><item><term>D2 receptors</term></item><item><term>Parkinson's disease</term></item><item><term>Positron emission tomography</term></item><item><term>Raclopride</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1995-04-24">Registration</change><change when="1995-03-07">Modified</change><change when="1995">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>JNS</jid><aid>9500137Q</aid><ce:pii>0022-510X(95)00137-Q</ce:pii><ce:doi>10.1016/0022-510X(95)00137-Q</ce:doi><ce:copyright type="unknown" year="1995"></ce:copyright><ce:doctopics><ce:doctopic><ce:text>Clinical section</ce:text></ce:doctopic></ce:doctopics></item-info><head><ce:dochead><ce:textfn>Research article</ce:textfn></ce:dochead><ce:title>Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [<ce:sup loc="pre">11</ce:sup>C]raclopride</ce:title><ce:author-group><ce:author><ce:given-name>Juha O.</ce:given-name><ce:surname>Rinne</ce:surname><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Arto</ce:given-name><ce:surname>Laihinen</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Hanna</ce:given-name><ce:surname>Ruottinen</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Ulla</ce:given-name><ce:surname>Ruotsalainen</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Kjell</ce:given-name><ce:surname>Någren</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>c</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Pertti</ce:given-name><ce:surname>Lehikoinen</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>c</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Vesa</ce:given-name><ce:surname>Oikonen</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>U.K.</ce:given-name><ce:surname>Rinne</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>Department of Neurology, University of Turku, SF-20520 Turku, Finland</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>Turku University Cyclotron-PET Center, PET Unit, Turku, Finland</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>c</ce:label><ce:textfn>Turku University Cyclotron-PET Center, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Corresponding author. Tel.: (+358-21) 261 1700; Fax: (+358-21) 261 1709.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="25" month="8" year="1994"></ce:date-received><ce:date-revised day="7" month="3" year="1995"></ce:date-revised><ce:date-accepted day="24" month="4" year="1995"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Striatal dopamine D2 receptors were studied, using positron emission tomography (PET), in 10 patients with early Parkinson's disease without any antiparkinsonian medication and in 14 healthy controls. [<ce:sup loc="pre">11</ce:sup>C]Raclopride was used as ligand and an equilibrium method was applied. The maximum count of receptors (<ce:italic>B</ce:italic><ce:inf>max</ce:inf>) and their dissociation constant (<ce:italic>K</ce:italic><ce:inf>d</ce:inf>) were calculated according to the Scatchard principle. In parkinsonian patients, the <ce:italic>B</ce:italic><ce:inf>max</ce:inf> of D2 receptors was increased in the putamen contralateral to the predominant symptoms, as compared to the opposite putamen, by 33% (<ce:italic>p</ce:italic> = 0.0008). In the caudate nucleus no significant side to side differences was noted. On comparison with age-matched healthy controls, <ce:italic>B</ce:italic><ce:inf>max</ce:inf> values in the putamen (<ce:italic>p</ce:italic> = 0.0012) but not in the caudate nucleus contralateral to the side of predominant clinical symptoms were increased in PD patients. The <ce:italic>K</ce:italic><ce:inf>d</ce:inf> values were unchanged. The difference in putaminal <ce:italic>B</ce:italic><ce:inf>max</ce:inf> values between the opposite hemispheres correlated with the difference in the severity of parkinsonian motor symptoms between the two body sides (<ce:italic>r</ce:italic> = 0.69, <ce:italic>p</ce:italic> = 0.03). The present results show that there is both a relative and absolute increase in the number of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Dopamine receptors</ce:text></ce:keyword><ce:keyword><ce:text>D2 receptors</ce:text></ce:keyword><ce:keyword><ce:text>Parkinson's disease</ce:text></ce:keyword><ce:keyword><ce:text>Positron emission tomography</ce:text></ce:keyword><ce:keyword><ce:text>Raclopride</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [</title></titleInfo><name type="personal"><namePart type="given">Juha O.</namePart><namePart type="family">Rinne</namePart><affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</affiliation><description>Corresponding author. Tel.: (+358-21) 261 1700; Fax: (+358-21) 261 1709.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Arto</namePart><namePart type="family">Laihinen</namePart><affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hanna</namePart><namePart type="family">Ruottinen</namePart><affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ulla</namePart><namePart type="family">Ruotsalainen</namePart><affiliation>Turku University Cyclotron-PET Center, PET Unit, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kjell</namePart><namePart type="family">Någren</namePart><affiliation>Turku University Cyclotron-PET Center, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pertti</namePart><namePart type="family">Lehikoinen</namePart><affiliation>Turku University Cyclotron-PET Center, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vesa</namePart><namePart type="family">Oikonen</namePart><affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U.K.</namePart><namePart type="family">Rinne</namePart><affiliation>Department of Neurology, University of Turku, SF-20520 Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1995</dateIssued><dateValid encoding="w3cdtf">1995-04-24</dateValid><dateModified encoding="w3cdtf">1995-03-07</dateModified><copyrightDate encoding="w3cdtf">1995</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Striatal dopamine D2 receptors were studied, using positron emission tomography (PET), in 10 patients with early Parkinson's disease without any antiparkinsonian medication and in 14 healthy controls. [11C]Raclopride was used as ligand and an equilibrium method was applied. The maximum count of receptors (Bmax) and their dissociation constant (Kd) were calculated according to the Scatchard principle. In parkinsonian patients, the Bmax of D2 receptors was increased in the putamen contralateral to the predominant symptoms, as compared to the opposite putamen, by 33% (p = 0.0008). In the caudate nucleus no significant side to side differences was noted. On comparison with age-matched healthy controls, Bmax values in the putamen (p = 0.0012) but not in the caudate nucleus contralateral to the side of predominant clinical symptoms were increased in PD patients. The Kd values were unchanged. The difference in putaminal Bmax values between the opposite hemispheres correlated with the difference in the severity of parkinsonian motor symptoms between the two body sides (r = 0.69, p = 0.03). The present results show that there is both a relative and absolute increase in the number of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease.</abstract><note type="content">Section title: Research article</note><subject><genre>Article category</genre><topic>Clinical section</topic></subject><subject><genre>Keywords</genre><topic>Dopamine receptors</topic><topic>D2 receptors</topic><topic>Parkinson's disease</topic><topic>Positron emission tomography</topic><topic>Raclopride</topic></subject><relatedItem type="host"><titleInfo><title>Journal of the Neurological Sciences</title></titleInfo><titleInfo type="abbreviated"><title>JNS</title></titleInfo><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">199510</dateIssued></originInfo><identifier type="ISSN">0022-510X</identifier><identifier type="PII">S0022-510X(00)X0011-1</identifier><part><date>199510</date><detail type="volume"><number>132</number><caption>vol.</caption></detail><detail type="issue"><number>2</number><caption>no.</caption></detail><extent unit="issue pages"><start>97</start><end>250</end></extent><extent unit="pages"><start>156</start><end>161</end></extent></part></relatedItem><identifier type="istex">809F6EC7C0EA6A5FF989A13C81E2B878D81F912B</identifier><identifier type="DOI">10.1016/0022-510X(95)00137-Q</identifier><identifier type="PII">0022-510X(95)00137-Q</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/809F6EC7C0EA6A5FF989A13C81E2B878D81F912B/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">CLINICAL NEUROLOGY</classCode><classCode scheme="WOS">NEUROIMAGING</classCode><classCode scheme="WOS">NEUROSCIENCES</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002279 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002279 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:809F6EC7C0EA6A5FF989A13C81E2B878D81F912B
|texte= Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride
}}
| This area was generated with Dilib version V0.6.23. |  |